ClinicalTrials.gg
RecruitingNCT07096011SPROUTUpdated Nov 17, 2026

Studying Phenotypic Risks for Obesity and Underlying Traits in Young Infants

An observational study in Infant Body Composition and Metabolism, Metabolism and Energy Expenditure, sponsored by Pennington Biomedical Research Center. Recruiting at 1 site in United States. Open to participants aged 2 Weeks to 16 Weeks, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Pennington Biomedical Research Center · Observational

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 3 months later.
Updated Nov 17, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
40
Ages
2 Weeks to 16 Weeks
Sex
All
01

Study summary

The purpose of this research study is to understand how infants metabolize different meals and to develop clinical tools which identify infants as having two different phenotypes. The phenotypes are the 1) metabolic "thriftiness" and 2) the metabolic flexibility.

Read the detailed description

The purpose of this research study is to understand how infants metabolize different meals and to develop clinical tools which identify infants as having two different phenotypes. This will be accomplished by providing two meal test stimuli to infant participants (human milk and infant formula). Energy expenditure and respiratory exchange ratio will be obtained before and after the meals to calculate the delta in both. From there, two phenotypes will be identified. The first phenotypes is metabolic "thriftiness", which will be defined by the energy expenditure after consuming two standard meals. The second phenotype is the degree of metabolic flexibility and will be defined by substrate oxidation (using respiratory exchange ratio) following two standard meals.

02

Conditions studied

  • Infant Body Composition and Metabolism
  • Metabolism
  • Energy Expenditure
  • Infant Formula
  • Human Milk, Breast Milk
  • Metabolic Flexibility

Keywords

  • infant
  • metabolism
  • energy expenditure
  • infant formula
  • breast milk
  • human milk
  • thrifty phenotype
  • metabolic flexibility
03

In context

Lead sponsor

Pennington Biomedical Research Center is the lead sponsor of 284 studies on the registry; 30 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
2 Weeks to 16 Weeks
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Up to 40 infants who are less than 17 weeks will be recruited to participate in this study.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged 2 weeks to less than 17 weeks at screening
  • Being fed human milk as a primary source of food
  • Be willing to consume one meal of infant formula
  • Be willing to complete a DXA measurement

Exclusion criteria

Exclusion Criteria:

  • Unable to complete the screening visit and two clinic visits within 14 days
  • Born with health conditions that would render procedures unsafe
  • Born earlier than 35 days and 0 weeks gestation
  • Eating supplemental foods
  • Physician diagnosed feeding difficulties that may require a special type of nipple for bottle feeding
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
40 participants (estimated)
Patient registry
No
Biospecimen retention
Samples without dna

Interventions

  • OtherMeal Test - Human Milk

    Infants will be fed a mixed meal test (meal challenge test) of human milk from his/her human milk donor (e.g., mother). Since all infants enrolled in the study consume human milk as a primary food source, this meal challenge test represents their standard meal, at a larger size. The meal test is provided inside a metabolic chamber to measure energy expenditure (VCO2 and VO2) before and after the meal. The amount of human milk that the infant is fed is estimated using the age and sex specific equations from the 2023 DRI for infants aged 0-2 years. Infants will be provided 20% of their predicted energy needs, which is equivalent to between 4-6 ounces of food for most infants of this age. The caloric content for human milk is be estimated at 20 kcals/ounce.

  • OtherMeal Test - Infant Formula

    Infants will be fed a mixed meal test (meal challenge test) of ready-to-feed infant formula. Since all infants enrolled in the study consume human milk as a primary food source, this meal challenge test represents a meal different from their habitual food intake and is a standard meal that all participants receive. The meal test is provided inside a metabolic chamber to measure energy expenditure (VCO2 and VO2) before and after the meal. The amount of infant formula that the infant is fed is estimated using the age and sex specific equations from the 2023 DRI for infants aged 0-2 years. Infants will be provided 20% of their predicted energy needs, which is equivalent to between 4-6 ounces of food for most infants of this age. The caloric content for the ready-to-feed infant formula is 20 kcals/ounce.

06

What researchers measure

Primary outcomes

  1. Energy expenditure difference from baseline to postprandial

    Percent difference from baseline to postprandial energy expenditure

    Time frame: 60 minutes

  2. Energy expenditure difference from baseline to postprandial (2)

    Absolute difference between baseline and postprandial energy expenditure

    Time frame: 60 minutes

Secondary outcomes

  1. Thrifty and Spendthrift Phenotypes

    Number of infants with a thrifty and spendthrift phenotype

    Time frame: 60 minutes

  2. Metabolic flexibility

    Difference in respiratory exchange ratio from baseline to postprandial

    Time frame: 60 minutes

07

Study locations

1 of 1 sites recruiting
  • Pennington Biomedical Research Center
    Baton Rouge, Louisiana 70808, United States
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jul 2025 (actual). Primary completion is estimated for Dec 2027, 29 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 17, 2026: primary completion Apr 2027 → Dec 2027 and completion May 2027 → Dec 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2025
First posted
Jul 31, 2025
StartActual
Jul 28, 2025
Primary completionEst.
Dec 2027was Apr 2027
CompletionEst.
Dec 2027was May 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Apr 2027→Dec 2027
Nov 17, 2026
Study completion
May 2027→Dec 2027
Nov 17, 2026
Show all 1 update
  1. Nov 17, 2026
    Primary completion Apr 2027→Dec 2027
    Study completion May 2027→Dec 2027
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07096011
Responsible party
Emily W. Flanagan, MS, PhD (Principal Investigator, Pennington Biomedical Research Center) — Principal investigator
First posted
Jul 31, 2025
Start date
Jul 28, 2025
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 17, 2026

Study contacts

Abby A Altazan, MS
Contact
abby.altazan@pbrc.edu
225-763-2801

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion